BACKGROUND: Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking patients with head and neck cancer. The aim of this study was to validate the Speech Handicap Index (SHI) as the first speech-specific questionnaire in the English language. METHOD: In all, 55 consecutive patients in follow-up for oral and oropharyngeal cancer completed the SHI and University of Washington Quality of Life Questionnaire (UWQOL V.04). Thirty-two patients completed both questionnaires again 4 weeks later to address test-retest reliability. RESULTS: Internal consistency, test-retest reliability, construct validity, and group validity of the SHI were found to be highly significant (p < .01) using Cronbach's alpha, Spearman's correlation coefficient (r), and Mann-Whitney U tests. CONCLUSIONS: The SHI is a precise, highly reliable, and valid speech assessment tool for patients with head and neck cancer. Further dedicated studies using the SHI in patients with head and neck cancer would be useful.
BACKGROUND: Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking patients with head and neck cancer. The aim of this study was to validate the Speech Handicap Index (SHI) as the first speech-specific questionnaire in the English language. METHOD: In all, 55 consecutive patients in follow-up for oral and oropharyngeal cancer completed the SHI and University of Washington Quality of Life Questionnaire (UWQOL V.04). Thirty-two patients completed both questionnaires again 4 weeks later to address test-retest reliability. RESULTS: Internal consistency, test-retest reliability, construct validity, and group validity of the SHI were found to be highly significant (p < .01) using Cronbach's alpha, Spearman's correlation coefficient (r), and Mann-Whitney U tests. CONCLUSIONS: The SHI is a precise, highly reliable, and valid speech assessment tool for patients with head and neck cancer. Further dedicated studies using the SHI in patients with head and neck cancer would be useful.
Authors: Ivana Petrovic; Hina Panchal; Paula Demetrio De Souza Franca; Marisol Hernandez; Colleen C McCarthy; Jatin P Shah Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: Ingrid C Cnossen; Remco de Bree; Rico N P M Rinkel; Simone E J Eerenstein; Derek H F Rietveld; Patricia Doornaert; Jan Buter; Johannes A Langendijk; C René Leemans; Irma M Verdonck-de Leeuw Journal: Support Care Cancer Date: 2012-03-07 Impact factor: 3.603
Authors: Agnieszka Dzioba; Daniel Aalto; Georgina Papadopoulos-Nydam; Hadi Seikaly; Jana Rieger; Johan Wolfaardt; Martin Osswald; Jeffrey R Harris; Daniel A O'Connell; Cathy Lazarus; Mark Urken; Ilya Likhterov; Raymond L Chai; Erika Rauscher; Daniel Buchbinder; Devin Okay; Risto-Pekka Happonen; Ilpo Kinnunen; Heikki Irjala; Tero Soukka; Juhani Laine Journal: J Otolaryngol Head Neck Surg Date: 2017-09-04